English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 910039      在线人数 : 784
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版

    子类别

    期刊論文 [327/330]
    圖書 [1/1]
    會議論文/會議摘要 [115/179]

    邻近社群


    于重元 [19/19]
    劉柯俊 [85/98]
    劉滄梧 [119/125]
    劉界元(2003-2010) [3/3]
    夏和雄(1996-2012) [26/31]
    夏興國 [51/54]
    姜乃榕 [82/94]
    常慧如 [39/44]
    張俊彥 [234/254]
    張光裕 [69/79]
    張憶壽 [103/106]
    張文祥 [52/53]
    張書銘 [89/91]
    彭汪嘉康(1996-2007) [120/126]
    施能耀 [37/43]
    李家惠 [29/29]
    李岳倫 [48/49]
    林素芳 [32/32]
    楊奕馨 [41/42]
    江士昇 [88/90]
    沈哲宏 [14/16]
    洪文俊 [88/88]
    莊雙恩 [82/91]
    蔡坤志 [32/34]
    蔡慧珍 [66/71]
    蘇勇曄 [40/40]
    蘇振良 [24/25]
    郭靜娟 [71/76]
    陳尚鴻 [45/48]
    陳振陽 [72/72]
    陳美霞(2002-2009) [1/1]
    陳詩政 [2/2]
    陳雅雯 [38/39]
    黃智興 [55/55]
    黃道揚 [26/26]
    丁兆治(2000-2004) [5/5]
    其他 [464/471]
    劉敏(1996-2007) [60/62]
    劉玫英(2004-2006) [2/2]
    吳成文(1996-2008) [53/55]
    曾思文(1997-2007) [4/4]
    李冠德(1997-2004) [4/6]
    林景太(1999-2007) [5/5]
    楊文光(1996-1999) [21/21]
    王全正(1996-2003) [4/4]
    莊聲宏(1997-2004) [11/11]
    詹宗晃(2000-2008) [2/2]
    賴基銘(2004-2008) [41/47]
    阮麗蓉(2000-2006) [6/7]
    陳俊叡(2003-2007) [6/6]
    馬彥英(1997-1999) [1/1]
    黃奇英(2005-2007) [9/10]

    社群统计


    近3年内发表的文件:74(14.51%)
    含全文笔数:443(86.86%)

    文件下载次数统计
    下载大于0次:443(100.00%)
    下载大于100次:426(96.16%)
    全文下载总次数:178131(3.32%)

    最后更新时间: 2024-12-01 08:27

    上传排行

    数据加载中.....

    下载排行

    数据加载中.....

    RSS Feed RSS Feed
    跳至:
    或输入年份:
    由新到旧排序 由最旧的开始

    显示项目151-175 / 510. (共21页)
    << < 2 3 4 5 6 7 8 9 10 11 > >>
    每页显示[10|25|50]项目

    日期题名關聯
    2019-04-08 Predominant global glomerulosclerosis in patients of upper urinary tract urothelial carcinoma with pre-existing renal function impairment is a predictor of poor renal outcomes BMC Cancer. 2019 Apr 8;19:Article number 337.
    2019-03 A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens Gastric Cancer. 2019 Mar;22(2):344-354.
    2019-03 Foreword Hepatobiliary Surgery and Nutrition. 2019 Mar;8(Suppl. 1):S1.
    2019-02 ASPM promotes prostate cancer stemness and progression by augmenting Wnt-Dvl-3-beta-catenin signaling Oncogene. 2019 Feb;38(8):1340-1353.
    2019-02 ASPM promotes prostate cancer stemness and progression by augmenting Wnt-Dvl-3-beta-catenin signaling [Erratum: Oncogene. 2019 Feb;38(8):1340-1353.] Oncogene. 2019 Feb;38(8):1354.
    2019-02 Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: Interim results of a randomized, phase II trial (attraction-4) Annals of Oncology. 2019 Feb;30(2):250-258.
    2019-02 NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors European Journal of Cancer. 2019 Feb;108:78-87.
    2019-02 Mutational landscape by targeted next-generation sequencing in EBV-associated lymphoepithelioma-like cholangiocarcinoma Journal of Clinical Oncology. 2019 Feb;37(4, Suppl.):Abstract number 269.
    2019-02 A multicenter, phase Ib/2 study of varlitinib plus gemcitabine and cisplatin (gem/cis) for treatment of naive, advanced, or metastatic biliary tract cancer (BTC) Journal of Clinical Oncology. 2019 Feb;37(4, Suppl.):Abstract number 319.
    2019-02 Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2 Journal of Clinical Oncology. 2019 Feb;37(4, Suppl.):Abstract number 8.
    2019-02 A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements Journal of Clinical Oncology. 2019 Feb;37(4, Suppl.):Abstract number TPS468.
    2019-01 Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin European Journal of Cancer. 2019 Jan;106:24-33.
    2019-01 Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic gastric cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS Annals of Oncology. 2019 Jan;30(1):19-33.
    2019-01 Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic oesophageal cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS Annals of Oncology. 2019 Jan;30(1):34-43.
    2019-01 Beta-catenin-activated autocrine PDGF/Src signaling is a therapeutic target in pancreatic cancer Theranostics. 2019 Jan;9(2):324-336.
    2018-12-20 Protein arginine methyltransferase 3 enhances chemoresistance in pancreatic cancer by methylating hnRNPA1 to increase ABCG2 expression Cancers. 2018 Dec 20;11(1):Article number 8.
    2018-12 c-Myc promotes lymphatic metastasis of pancreatic neuroendocrine tumor through VEGFC upregulation Cancer Science. 2018 Dec;109(Suppl. 2):866.
    2018-12 The epidemiology of gastric cancer in the era of H. pylori eradication: A nation-wide registry-based study in Taiwan Cancer Science. 2018 Dec;109(Suppl. 2):1437.
    2018-12 FOXO3a-driven alternation of metabolism dictates the gemcitabine sensitivity Cancer Science. 2018 Dec;109(Suppl. 2):871.
    2018-11-13 From friend to enemy: Dissecting the functional alteration of immunoregulatory components during pancreatic tumorigenesis International Journal of Molecular Sciences. 2018 Nov 13;19(11):Article number 3584.
    2018-11-07 Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial European Journal of Cancer. 2018 Nov 7;105:71-78.
    2018-11 The incidence and survival of pancreatic cancer by histology, including rare subtypes: A nation-wide cancer registry-based study from Taiwan Cancer Medicine. 2018 Nov;7(11):5775-5788.
    2018-11 TCOG T1308 study: The final results of a phase II trial of modified gemcitabine plus S-1 combination as the first-line treatment in patients with advanced biliary tract cancer Annals of Oncology. 2018 Nov;29(Suppl. 9):50.
    2018-11 Liposomal irinotecan (nal-IRI) plus 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) progressing on gemcitabine-based treatment: Further subgroup analyses of the pivotal NAPOLI-1 study Annals of Oncology. 2018 Nov;29(Suppl. 9):Meeting Abstract 200P.
    2018-11 M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor beta (TGF-beta) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): Efficacy by BTC subtype Annals of Oncology. 2018 Nov;29(Suppl. 9):Meeting Abstract 153O.

    显示项目151-175 / 510. (共21页)
    << < 2 3 4 5 6 7 8 9 10 11 > >>
    每页显示[10|25|50]项目

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈